Evidence map›Paper›PMID 40140552›Full record

ReviewProstate cancer and prostatic diseases2026

New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review.

Sangeet Ghai, Tiffany T Ni, Christian P Pavlovich, Jurgen J Futterer, George R Schade, Rafael Sanchez-Salas, Francois Cornud, Scott Eggener, John F Feller, Arvin K George and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sangeet Ghai *Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada. Sangeet.Ghai@uhn.ca.ORCID http://orcid.org/0000-0001-9451-0594
Tiffany T Ni *Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.
Christian P PavlovichJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jurgen J FuttererDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
George R SchadeDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Rafael Sanchez-SalasDepartment of Surgery, Division of Urology, McGill University, Montreal, QC, Canada.
Francois CornudDepartment of Radiology, Clinique de l'Alma, 75007, Paris, France.
Scott EggenerDepartment of Surgery, Section of Urology, University of Chicago, Chicago, IL, USA.
John F FellerHalo Diagnostics, Indian Wells, CA, USA.
Arvin K GeorgeDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Arnauld VillersDepartment of Urology, University Hospital, Lille, France.
Jean de la RosetteDepartment of Urology, Istanbul Medipol University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-6308-1763

Funding

American Cancer Society (American Cancer Society, Inc.) RSG2117101
6 · The paper itself

Abstract

introductionProstate cancer (PCa) management poses challenges due to treatment-related morbidities associated with conventional therapies. Focal therapy (FT) is emerging as a promising alternative for intermediate-risk PCa, aiming to selectively target localized cancerous lesions while preserving healthy tissue. This review explores emerging FT modalities for PCa treatment, focusing on transrectal MRI-guided focused ultrasound surgery (MRgFUS), transurethral ultrasound ablation (TULSA), focal laser ablation (FLA), and histotripsy.

methodsA comprehensive literature search was conducted to identify studies and clinical trials related to FT. Relevant articles were selected and data were synthesized to provide insights into the efficacy and feasibility of MRgFUS, TULSA, FLA, and histotripsy for FT.

resultsMRgFUS utilizes transrectal high-intensity focused ultrasound under MRI guidance to selectively ablate cancerous tissue, demonstrating positive outcomes in oncologic control and preservation of urinary and sexual function. TULSA employs transurethral delivery of high-intensity ultrasound energy under MRI guidance, showing promising results for whole gland treatment. FLA benefits from precise ablation, indicating effectiveness in tumor destruction while preserving quality-of-life. Histotripsy, a mechanical ablation method, exhibits promise by inducing tissue fractionation through bubble activity, offering advantages such as tissue selectivity and real-time treatment monitoring.

conclusionEmerging FT modalities present promising alternatives for the management of localized PCa, offering personalized treatment. Further research and clinical trials are warranted to establish the long-term efficacy of these techniques in PCa management.

Indexed as

High-Intensity Focused Ultrasound AblationLaser TherapyMagnetic Resonance ImagingProstatic NeoplasmsSurgery, Computer-AssistedUltrasound, High-Intensity Focused, TransrectalHumansMale

Identifiers

PMID40140552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.